Table3_Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19.docx (16.75 kB)
Download file

Table3_Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19.docx

Download (16.75 kB)
dataset
posted on 21.03.2022, 05:00 authored by Suyu Gao, Qingqing Yang, Xuanxuan Wang, Wen Hu, Yun Lu, Kun Yang, Qiaoli Jiang, Wenjing Li, Haibo Song, Feng Sun, Hong Cheng

The outbreak of coronavirus disease 2019 (COVID-19) has led to the emergence of global health care. In this study, we aimed to explore the association between drug treatments and the incidence of drug-induced liver injury (DILI) in hospitalized patients with COVID-19. A retrospective study was conducted on 5113 COVID-19 patients in Hubei province, among which 395 incurred liver injury. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by Cox proportional hazards models. The results showed that COVID-19 patients who received antibiotics (HR 1.97, 95% CI: 1.55–2.51, p < 0.001), antifungal agents (HR 3.10, 95% CI: 1.93–4.99, p < 0.001) and corticosteroids (HR 2.31, 95% CI: 1.80–2.96, p < 0.001) had a higher risk of DILI compared to non-users. Special attention was given to the use of parenteral nutrition (HR 1.82, 95% CI: 1.31–2.52, p < 0.001) and enteral nutrition (HR 2.71, 95% CI: 1.98–3.71, p < 0.001), which were the risk factors for liver injury. In conclusion, this study suggests that the development of DILI in hospitalized patients with COVID-19 needs to be closely monitored, and the above-mentioned drug treatments may contribute to the risk of DILI.

History

References